2. Search Result
Search Result
Pathways Recommended: Stem Cell/Wnt Cell Cycle/DNA Damage
Results for "

epidermal cells

" in MedChemExpress (MCE) Product Catalog:

49

Inhibitors & Agonists

1

Screening Libraries

2

Biochemical Assay Reagents

1

Peptides

1

Inhibitory Antibodies

9

Natural
Products

1

Isotope-Labeled Compounds

2

Click Chemistry

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-100923
    H-9 Dihydrochloride

    		PKA 5-HT Receptor EGFR Neurological Disease
    H-9 Dihydrochloride is a PKA (protein kinase) inhibitor. H-9 Dihydrochloride (10 μM) significantly reduces the excitatory response to 5-HT. H-9 Dihydrochloride also has a direct effect on pharyngeal activity. H-9 Dihydrochloride inhibits signal-transduction and cell growth in EGF (epidermal growth factor)-dependent epithelial cell lines .
    H-9 Dihydrochloride
  • HY-144680
    BLU-945

    ZL-2313

    		 EGFR Cancer
    BLU-945 is a potent, highly selective, reversible and orally active epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKIs). BLU-945 can effectively inhibit EGFR with L858R and/or exon 19 deletion mutation, T790M mutation and C797S mutation. BLU-945 can be used for the research of lung cancer including non-small cell lung cancer (NSCLC) .
    BLU-945
  • HY-113008B
    trans-Urocanic acid

    (E)-Urocanic acid; trans-UCA

    		 Endogenous Metabolite Inflammation/Immunology
    trans-urocanic acid (trans-UCA), a natural epidermal constituent, inhibits human natural killer cell (NK) activity in vitro. trans-urocanic acid is active in regulating an immune function .
    trans-Urocanic acid
  • HY-N0128
    Sclareol
    2 Publications Verification

    		 Apoptosis Cancer
    Sclareol is isolated from Salvia sclarea with anticarcinogenic activity. Sclareol shows strong cytotoxic activity against mouse leukemia?(P-388), human epidermal?carcinoma?(KB) cells and human?leukemia?cell lines. Sclareol induces cell apoptosis .
    Sclareol
  • HY-U00002
    ZD-4190

    		VEGFR EGFR Cancer
    ZD-4190 is a potent, orally available inhibitor of the vascular endothelial cell growth factor receptor 2 (VEGFR2) and of epidermal growth factor receptor (EGFR) signalling, used for the treatment of cancer.
    ZD-4190
  • HY-N1658
    2,3-Dihydroisoginkgetin

    		Tyrosinase Others
    2,3-Dihydroisoginkgetin, a biflavonoid, is a inhibitor of Tyrosinase, with 36.84% inhibition at 0.1 mM. 2,3-Dihydroisoginkgetin shows less toxicity in HEMn (human epidermal melanocytes) cells, with an IC50 of 86.16 μM .
    2,3-Dihydroisoginkgetin
  • HY-117081
    C30(ω-hydroxy) Ceramide (d18:1/30:0)

    		Endogenous Metabolite Others
    C30(ω-hydroxy) Ceramide (d18:1/30:0), a sphingolipid, is an epidermis-specifically vital component of the water barrier in mammalian skin. C30(ω-hydroxy) Ceramide (d18:1/30:0) is expressed in epidermal keratinocytes and male germ cells during their differentiation and maturation. C30(ω-hydroxy) Ceramide (d18:1/30:0) deficiency in the epiderm of Elovl4 deletion or mutation mice .
    C30(ω-hydroxy) Ceramide (d18:1/30:0)
  • HY-NP145
    Epidermal Growth Factor,murine submaxillary gland

    		Biochemical Assay Reagents Metabolic Disease
    Epidermal Growth Factor, murine submaxillary gland is a biologically active polypeptide isolated from mouse submandibular gland. Epidermal Growth Factor, murine submaxillary gland is a mitogen that stimulates the growth of epithelial cells, fibroblasts and glial cells under various experimental conditions .
    Epidermal Growth Factor,murine submaxillary gland
  • HY-160613
    EGFR/HER2-IN-11

    		EGFR Cancer
    EGFR/HER2-IN-11 (compound 20) is an orally active dual inhibitor for human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR), with IC50s of 7.7 and 22 nM, respectively. EGFR/HER2-IN-11 exhibits antitumor efficacy and inhibits proliferation against cancer cells BT-474 with GI50 of 601 nM .
    EGFR/HER2-IN-11
  • HY-162099
    VEGFR-IN-4

    		EGFR Cancer
    VEGFR-IN-4 (Compound 6e) is an epidermal growth factor receptor (EGFR) inhibitor. VEGFR-IN-4 has potent antiproliferative activity with an IC50 value of 24.6nM against HCC827 cells .
    VEGFR-IN-4
  • HY-N0128R
    Sclareol (Standard)

    		Apoptosis Cancer
    Sclareol (Standard) is the analytical standard of Sclareol. This product is intended for research and analytical applications. Sclareol is isolated from Salvia sclarea with anticarcinogenic activity. Sclareol shows strong cytotoxic activity against mouse leukemia (P-388), human epidermal carcinoma (KB) cells and human leukemia cell lines. Sclareol induces cell apoptosis .
    Sclareol (Standard)
  • HY-18764
    BpV(pic) potassium hydrate

    		PTEN Metabolic Disease
    BpV(pic) potassium hydrate is a PTEN inhibitor with IC50 31 nM. BpV(pic) potassium hydrate is also an insulin simulator that activates insulin receptor kinase in cultured liver cancer cells, stimulates adipogenesis in adipocytes, and inhibits the dephosphorylation of autophosphorylated insulin receptors and epidermal growth factor receptors in rat hepatosomes .
    BpV(pic) potassium hydrate
  • HY-N2459
    Peonidin chloride

    YGM-6 chloride

    		 COX Cancer
    Peonidin chloride is an O-methylated anthocyanidin that functions as a primary plant pigment, endowing purplish-red hues to flowers such as the peony, from which it takes its name, as well as berries and vegetables. Peonidin chloride exhibits chemopreventive, as well as anti-inflammatory activities on cancer cells in vitro, blocking COX-2 expression and transformation in JB6 P+ mouse epidermal cells.
    Peonidin chloride
  • HY-149517
    EGFR/BRAFV600E-IN-2

    		EGFR Cancer
    E07 aptamer is an aptamer that targets human epidermal growth factor receptor (hEGFR). E07 aptamer can compete with EGF for binding, binds to a novel epitope on EGFR. E07 aptamer binds to cells expressing EGFR, blocks receptor autophosphorylation, and prevents proliferation of tumor cells in three-dimensional matrices. E07 aptamer can be used for tomor disease research .
    EGFR/BRAFV600E-IN-2
  • HY-N2459R
    Peonidin (chloride) (Standard)

    		COX Cancer
    Peonidin (chloride) (Standard) is the analytical standard of Peonidin (chloride). This product is intended for research and analytical applications. Peonidin chloride is an O-methylated anthocyanidin that functions as a primary plant pigment, endowing purplish-red hues to flowers such as the peony, from which it takes its name, as well as berries and vegetables. Peonidin chloride exhibits chemopreventive, as well as anti-inflammatory activities on cancer cells in vitro, blocking COX-2 expression and transformation in JB6 P+ mouse epidermal cells.
    Peonidin (chloride) (Standard)
  • HY-101959
    Tyrphostin AG213

    AG213

    		 EGFR Topoisomerase Cancer
    Tyrphostin AG213 (AG213) is an inhibitor of epidermal growth factor receptor (EGFR) protein tyrosine kinase (IC50=0.85 μM). Tyrphostin AG213 inhibits tyrosine kinase activity IC50=2.4 μM) and topoisomerase II (IC100=50 μM). Tyrphostin AG213 can induce nonapoptotic cell programmed death in tumor cells .
    Tyrphostin AG213
  • HY-122564
    Pyrimidyn 7

    		Dynamin Others
    Pyrimidyn 7 is an inhibitor of dynamin I/II with IC50 values of 1.1 μM and 1.8 μM, respectively. Pyrimidyn 7 competitively inhibits the interactions between GTP and phospholipids with dynamin I. Additionally, Pyrimidyn 7 reversibly inhibits clathrin-mediated endocytosis (CME) of transferrin and epidermal growth factor (EGF) in various non-neuronal cell linecell [1.
    Pyrimidyn 7
  • HY-125322
    Reveromycin C

    		Bacterial Infection
    Reveromycin C is a polyketide originally isolated from Streptomyces that has antifungal activity against C. albicans (MICs=2.0 and >500 μg/mL at pH 3 and 7.4, respectively). Reveromycin C inhibits EGF-induced mitogenic activity in the Balb/MK mouse epidermal cell line. It also reverses the morphology of sarcoma-virus-transformed NRK rat kidney cells (EC50=1.58 μg/mL) and inhibits proliferation of KB cells and K562 human chronic myelogenous leukemia cells (IC50=2.0 μg/mL for both).
    Reveromycin C
  • HY-144048
    EGFR-IN-31

    		EGFR Cancer
    EGFR-IN-31 is a potent inhibitor of EGFR. Overexpression and mutation of the epidermal growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC. EGFR-IN-31 has the potential for the research of diseases associated with EGFR mutations (extracted from patent WO2021185298A1, compound 2) .
    EGFR-IN-31
  • HY-144049
    EGFR-IN-32

    		EGFR Cancer
    EGFR-IN-32 is a potent inhibitor of EGFR. Overexpression and mutation of the epidermal growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC. EGFR-IN-32 has the potential for the research of diseases associated with EGFR mutations (extracted from patent WO2021185297A1, compound 2) .
    EGFR-IN-32
  • HY-145867
    EGFR-IN-45

    		Topoisomerase EGFR CDK Apoptosis Cancer
    EGFR-IN-45 is a potent epidermal growth factor receptor (EGFR) pan inhibitor, with IC50s of 0.4 µM and 1.6 µM for EGFR and CDK2, respectively. EGFR-IN-45 also inhibit Topo I and Topo II. EGFR-IN-45 arrests cancer cells in the pre-G1 phase and induces apoptosis .
    EGFR-IN-45
  • HY-163176
    WB518

    		STAT Inflammation/Immunology
    WB518 is a potent STAT3 inhibitor. WB518 effectively inhibits STAT3 activation and Keratin 17 expression. WB518 effectively alleviates imiquimod (HY-B0180) and TPA (HY-18739)-induced animal psoriasis by inhibiting STAT3 phosphorylation and Keratin 17 .
    WB518
  • HY-133091
    7-Ethoxycoumarin

    7-O-Ethylumbelliferone

    		 Cytochrome P450 Metabolic Disease
    7-Ethoxycoumarin is a substrate of cytochrome P450 (CYP450). 7-Ethoxycoumarin has been used for the functional characterization of various CYPs and for the generation of 7-hydroxycoumarin (HY-N0573) .
    7-Ethoxycoumarin
  • HY-120857
    BPIQ-II hydrochloride

    PD 158294

    		 EGFR Others
    BPIQ-II is a linear imidazoloquinazoline that potently inhibits the tyrosine kinase activity of the epidermal growth factor receptor (EGFR; IC50=8 pM). It is selective for EGFR over an assortment of other tyrosine and serine/threonine kinases. Cellular studies indicate that BPIQ-II can enter cells and very selectively shut down EGF-stimulated signal transmission by binding competitively at the ATP site of EGFR.
    BPIQ-II hydrochloride
  • HY-12965B
    (Z)-S49076 hydrochloride

    		TAM Receptor Cancer
    (Z)-S49076 hydrochloride is an orally active inhibitor of MET and AXL that blocks the downstream signaling of these receptors both in vitro and in vivo, inhibiting the proliferation and migration of tumor cells and suppressing tumor growth in xenograft models. (Z)-S49076 hydrochloride is capable of overcoming the resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) due to MET amplification in Erlotinib (HY-50896)-resistant cell lines both in vitro and in vivo. (Z)-S49076 hydrochloride can be used for research in non-small cell lung cancer (NSCLC) .
    (Z)-S49076 hydrochloride
  • HY-171124
    Tilatamig samrotecan

    AZD9592

    		 Topoisomerase DNA/RNA Synthesis Cancer
    Tilatamig samrotecan (AZD9592) is an antibody-drug conjugate (ADC) used to deliver topoisomerase I inhibitors (TOP1i), targeting the epidermal growth factor receptor (EGFR) and c-MET, with anti-tumor activity. Tilatamig samrotecan (AZD9592) can induce DNA double-strand breaks, increase the expression of pRAD50 and γH2AX, and inhibit the growth of non-small cell lung cancer .
    Tilatamig samrotecan
  • HY-164487
    JBJ-08-178-01

    		Proteasome Cancer
    JBJ-08-178-01 is a mutant-selective tyrosine kinase inhibitor against human epidermal growth factor receptor 2 (HER2) with an antitumoral activity. JBJ-08-178-01 reduces both the kinase activity and protein levels of HER2 by inducing proteasomal degradation of the receptor in lung cancer. JBJ-08-178-01 is promising for research of non-small-cell lung cancer .
    JBJ-08-178-01
  • HY-150610
    EGFR-IN-69

    		EGFR Cancer
    EGFR-IN-69 (compound 17g) is a potent EGFR inhibitor, with IC50 values of 4.3, 6.6 and 25.6 nM against EGFR L858R/T790M/C797S, EGFR L858R/T790M, and EGFR 19del/T790M/C797S, respectively. EGFR-IN-69 can be used for non-small-cell-lung-cancer (NSCLC) research .
    EGFR-IN-69
  • HY-170968
    EGFR-IN-150

    		EGFR Apoptosis Cancer
    EGFR-IN-150 is an EGFR inhibitor that effectively suppresses the phosphorylation of mutant epidermal growth factor receptor (EGFR) and its downstream AKT signaling pathway, thereby exerting antitumor effects and inducing HMOX1 expression to trigger ferroptosis. EGFR-IN-150 exhibits an IC50 of 0.386 μM against the non-small cell lung cancer (NSCLC) cell line H1975, and significantly inhibits colony formation and migration of both H1975 and A549 cells while inducing apoptosis. In addition, EGFR-IN-150 markedly suppresses tumor growth in the H1975 cell-derived xenograft (CDX) mouse model. EGFR-IN-150 holds promise for research related to non-small cell lung cancer .
    EGFR-IN-150
  • HY-101180
    C2 Ceramide
    1 Publications Verification

    Ceramide 2

    		 Phosphatase Mitochondrial Metabolism Apoptosis Autophagy Metabolic Disease Endocrinology
    C2 Ceramide (Ceramide 2) is the main lipid of the stratum corneum and a protein phosphatase 1 (PP1) activator. C2 Ceramide activates PP2A and ceramide-activated protein phosphatase (CAPP). C2 Ceramide induces cells differentiation, autophagy and apoptosis, inhibits mitochondrial respiratory chain complex III. C2 Ceramide is also a skin conditioning agent that protects the epidermal barrier from water loss .
    C2 Ceramide
  • HY-129510
    4-Methyl erlotinib

    		EGFR Cancer
    4-Methyl erlotinib, is a potent and selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. 4-Methyl erlotinib potently inhibits EGF-mediated tumor cell mitosis by reducing EGFr-specific tyrosine phosphorylation. Using a mouse model of human tumor transplantation, 4-Methyl erlotinib demonstrated significant and sustained suppression of EGFr phosphotyrosine levels, resulting in significant growth inhibition of EGFr-dependent human cancers .
    4-Methyl erlotinib
  • HY-144050
    EGFR-IN-33

    		EGFR Cancer
    EGFR-IN-33 is a potent inhibitor of EGFR. EGFR-IN-33 is an anti-tumor agent with low toxic side effects. EGFR-IN-33 is an acrylamide derivative compound. Overexpression and mutation of the epidermal growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC. EGFR-IN-33 has the potential for the research of diseases associated with EGFR mutations (extracted from patent WO2021185348A1, compound 13) .
    EGFR-IN-33
  • HY-144052
    EGFR-IN-35

    		EGFR Cancer
    EGFR-IN-35 is a potent inhibitor of EGFR. EGFR-IN-35 is an anti-tumor agent with low toxic side effects. EGFR-IN-35 is an acrylamide derivative compound. Overexpression and mutation of the epidermal growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC. EGFR-IN-35 has the potential for the research of diseases associated with EGFR mutations (extracted from patent WO2021185348A1, compound 11) .
    EGFR-IN-35
  • HY-144051
    EGFR-IN-34

    		EGFR Cancer
    EGFR-IN-34 is a potent inhibitor of EGFR. EGFR-IN-34 is an anti-tumor agent with low toxic side effects. EGFR-IN-35 is an acrylamide derivative compound. Overexpression and mutation of the epidermal growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC. EGFR-IN-34 has the potential for the research of diseases associated with EGFR mutations (extracted from patent WO2021185348A1, compound 12) .
    EGFR-IN-34
  • HY-144056
    EGFR-IN-39

    		EGFR Cancer
    EGFR-IN-39 is a potent inhibitor of EGFR. EGFR-IN-39 is an anti-tumor agent with low toxic side effects. EGFR-IN-39 is an acrylamide derivative compound. Overexpression and mutation of the epidermal growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC. EGFR-IN-39 has the potential for the research of diseases associated with EGFR mutations (extracted from patent WO2021185348A1, compound 2) .
    EGFR-IN-39
  • HY-144054
    EGFR-IN-37

    		EGFR Cancer
    EGFR-IN-37 is a potent inhibitor of EGFR. EGFR-IN-37 is an anti-tumor agent with low toxic side effects. EGFR-IN-39 is an acrylamide derivative compound. Overexpression and mutation of the epidermal growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC. EGFR-IN-37 has the potential for the research of diseases associated with EGFR mutations (extracted from patent WO2021185348A1, compound 7) .
    EGFR-IN-37
  • HY-144055
    EGFR-IN-38

    		EGFR Cancer
    EGFR-IN-38 is a potent inhibitor of EGFR. EGFR-IN-38 is an anti-tumor agent with low toxic side effects. EGFR-IN-33 is an acrylamide derivative compound. Overexpression and mutation of the epidermal growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC. EGFR-IN-38 has the potential for the research of diseases associated with EGFR mutations (extracted from patent WO2021185348A1, compound 4) .
    EGFR-IN-38
  • HY-101522
    CHMFL-EGFR-202

    		EGFR BMX Kinase Btk MEK Cancer
    CHMFL-EGFR-202 is a potent, irreversible inhibitor of epidermal growth factor receptor (EGFR) mutant kinase, with IC50s of 5.3 nM and 8.3 nM for drug-resistant mutant EGFR T790M and WT EGFR kinases, respectively. CHMFL-EGFR-202 exhibits ～10-fold selectivity for EGFR L858R/T790M against the EGFR wild-type in cells. CHMFL-EGFR-202 adopts a covalent “DFG-in-C-helix-out” inactive binding conformation with EGFR, with strong antiproliferative effects against EGFR mutant-driven nonsmall-cell lung cancer (NSCLC) cell lines .
    CHMFL-EGFR-202
  • HY-170438
    EGFR-IN-139

    		EGFR Cancer
    EGFR-IN-139 (compound PD 18) is an epidermal growth factor receptor (EGFR) inhibitor, with IC50s of 12.88 (wild type), 10.84 (L858R/T790M), 42.68 (L858R/T790M/C797S) nM, respectively. EGFR-IN-139 displays strong anticancer activity against A549 and H1975 cancer cell lines, which are highly expressed EGFR. EGFR-IN-139 has a strong selectivity to cancer cells. EGFR-IN-139 can be used for nonsmall cell lung cancer (NSCLC) research[1].
    EGFR-IN-139
  • HY-124152
    3,4-Dephostatin

    Methyl-3,4-dephostatin

    		 MAP3K MAP4K Phosphatase Neurological Disease
    3,4-Dephostatin (Methyl-3,4-dephostatin) is an inhibitor of protein-tyrosine phosphatase (PTPase). 3,4-Dephostatin accelerates nerve growth factor (NGF)-induced neurite formation in PC12h cells. 3,4-Dephostatin sustains the NGF-induced tyrosine phosphorylation of proteins, most prominently that of mitogen-activated protein (MAP) kinase. 3,4-Dephostatin also prolongs epidermal growth factor (EGF)-induced tyrosine phosphorylation and activation of MAP kinase .
    3,4-Dephostatin
  • HY-48999A
    FSK hydrochloride

    		Others Cancer
    FSK hydrochloride is fluorosulfonyloxybenzoyl-l-lysine, with a long and flexible aryl fluorosulfate-containing side chain that can reach protein sites that are difficult to reach by covalent linkage. FSK hydrochloride is a modified nanomolecule that targets the epidermal growth factor receptor (EGFR), creating a covalent binding that results in irreversible binding. FSK hydrochloride captures unknown enzyme-substrate interactions in living cells through genetically encoded chemical cross-linking, targeting residues beyond Cys, and cross-linking at the binding periphery. FSK hydrochloride enables the construction of bioreactive SuFEx systems for creating covalent bonds in different proteins in vitro and in vivo .
    FSK hydrochloride
  • HY-129510R
    4-Methyl erlotinib (Standard)

    		EGFR Cancer
    4-Methyl erlotinib (Standard) is the analytical standard of 4-Methyl erlotinib. This product is intended for research and analytical applications. 4-Methyl erlotinib, is a potent and selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. 4-Methyl erlotinib potently inhibits EGF-mediated tumor cell mitosis by reducing EGFr-specific tyrosine phosphorylation. Using a mouse model of human tumor transplantation, 4-Methyl erlotinib demonstrated significant and sustained suppression of EGFr phosphotyrosine levels, resulting in significant growth inhibition of EGFr-dependent human cancers .
    4-Methyl erlotinib (Standard)
  • HY-103291
    Sar-[D-Phe8]-des-Arg9-Bradykinin

    		Bradykinin Receptor Inflammation/Immunology Endocrinology
    Sar-[D-Phe8]-des-Arg9-Bradykinin is a agonist of B1 receptor. Sar-[D-Phe8]-des-Arg9-Bradykinin selectively amplifies the contractile response when incubation with human recombinant interleukin-1 β (IL-1 β) in rabbit aortic rings .
    Sar-[D-Phe8]-des-Arg9-Bradykinin
  • HY-N0447
    8-Gingerol
    4 Publications Verification

    		 TRP Channel Bacterial Apoptosis Autophagy STAT PERK EGFR PI3K Akt mTOR Caspase MMP Infection Cardiovascular Disease Inflammation/Immunology Cancer
    8-Gingerol can be found in the rhizome of ginger (Z. officinale) and has oral bioactivity. It activates TRPV1, with an EC50 value of 5.0 µM. 8-Gingerol inhibits COX-2 and also suppresses the growth of H. pylori in vitro. Additionally, 8-Gingerol exhibits anticancer, antioxidant, and anti-inflammatory properties by inhibiting the epidermal growth factor receptor (EGFR) and modulating its downstream STAT3/ERK pathway to suppress the proliferation, migration, and invasion of colorectal cancer cells. 8-Gingerol also exerts immunosuppressive effects by inhibiting oxidative stress, inducing cell cycle arrest, promoting apoptosis, and regulating autophagy. Furthermore, 8-Gingerol has cardioprotective effects. 8-Gingerol is promising for research in the fields of cancer, infection, immunosuppression, and cardiovascular diseases.
    8-Gingerol
  • HY-141582
    Ceramide 3

    N-Stearoyl phytosphingosine

    		 Biochemical Assay Reagents Others
    C18 Phytoceramide (t18:0/18:0) (Cer(t18:0/18:0)) is a bioactive sphingolipid found in the stratum corneum of Saccharomyces cerevisiae, wheat grain, and mammalian epidermis. Cer(t18:0/18:0) consists of a phytosphingosine backbone amine linked to a C18 fatty acid chain. Cer(t18:0/18:0) has the function of regulating apoptosis, cell differentiation, proliferation of smooth muscle cells and inhibition of mitochondrial respiratory chain. It also suppresses the expression of allergic cytokines IL-4, TNF-α, and transcription factors c-Jun and NF-κB in histone-stimulated mouse skin tissue. Formulations containing cer(t18:0/18:0) have been used as skin protectants in cosmetics as they reduce water loss and prevent epidermal dehydration and irritation.
    Ceramide 3
  • HY-164490
    LS-106

    		EGFR Apoptosis Cancer
    LS-106 is an orally active and potent inhibitor against epidermal growth factor receptor (EGFR) . LS-106 exhibits antitumor activities both in vitro and in vivo. LS-106 inhibits the kinase activities of EGFR 19del/T790M/C797S and EGFR L858R/T790M/C797S with IC50 values of 2.4 nmol/L and 3.1 nmol/L, respectively, which is more potent than Osimertinib (HY-15772). LS-106 induces Apoptosis, suppresses cell proliferation of tumor cells harboring EGFR 19del/T790M/C797S and leas to significant tumor regression in a C797S-mutant xenograft model .
    LS-106
  • HY-141582S
    Ceramide 3-d3

    N-Stearoyl phytosphingosine-d3

    		 Isotope-Labeled Compounds Biochemical Assay Reagents Others
    Ceramide 3-d3 (N-Stearoyl phytosphingosine-d3) is deuterium labeled Ceramide 3. C18 Phytoceramide (t18:0/18:0) (Cer(t18:0/18:0)) is a bioactive sphingolipid found in the stratum corneum of Saccharomyces cerevisiae, wheat grain, and mammalian epidermis. Cer(t18:0/18:0) consists of a phytosphingosine backbone amine linked to a C18 fatty acid chain. Cer(t18:0/18:0) has the function of regulating apoptosis, cell differentiation, proliferation of smooth muscle cells and inhibition of mitochondrial respiratory chain. It also suppresses the expression of allergic cytokines IL-4, TNF-α, and transcription factors c-Jun and NF-κB in histone-stimulated mouse skin tissue. Formulations containing cer(t18:0/18:0) have been used as skin protectants in cosmetics as they reduce water loss and prevent epidermal dehydration and irritation .
    Ceramide 3-d3
  • HY-P99941
    Retifanlimab

    		PD-1/PD-L1 Cancer
    Retifanlimab is an anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody (mAb). Retifanlimab can be used for the research of gastroesophageal adenocarcinoma (GEA) .
    Retifanlimab
  • HY-150782
    UNC-CA359

    		EGFR Cancer
    UNC-CA359 is a potent epidermal growth factor receptor (EGFR) inhibitor, with an IC50 value of 18 nM. UNC-CA359 exhibits strong anti-tumor activity, can be used to Chordoma research . UNC-CA359 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    UNC-CA359

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: